In this issue:
Initiating pharmacological treatment for type 2 diabetes in Australia
DPP-4 inhibitors, SGLT-2 inhibitors and GLP-1 agonists in white vs. Asian diabetics
Lyophilised and liquid avexitide for postbariatric hypoglycaemia
Whole-grain intake/processing, fruit/vegetable intake, and type 2 diabetes risk
Predictors for glycaemic progression in Chinese patients with type 2 diabetes
COVID-19: impact of lockdown on glucose control; diabetes and secondary hyperglycaemia outcomes
Linagliptin and CV/renal outcomes according to kidney function
Please login below to download this issue (PDF)